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Letters to the Editortotal. In the United Kingdom, approxi-
mately 3500 isolated bioprosthetic aor-
tic valve replacements are performed
per annum.Assuming 50% of these pa-
tients are eligible for the study and all
units participate, the study will take
more than 4 years to complete.
One of the main difficulties we
have encountered in the feasibility
phase of this study is recruitment of
patients with pure aortic valve
disease who do not have any forms
of arrhythmia or coronary artery
disease, thus already receiving aspirin
or warfarin. Ideally, a randomized
study is necessary. Unless this is
a multicenter international trial, suffi-
cient numbers of patients cannot be
recruited. We may then have to rely
on antithrombotic therapy in the
high-risk groups.
We would like to thank the British Heart
Foundation for supporting the feasibility
phase of this study.
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We thank the authors for their
comments regarding our recent article
discussing the necessity of immediate
postoperative anticoagulation in pa-
tients with bioprosthetic aortic valves.1
Although this exact topic has been
studied repeatedly over the past de-
cade, there continues to be a lack of
consensus, primarily owing to the ab-
sence of level 1 evidence. As the au-
thors point out, despite strong
evidence to advocate for/against an-
tithrombotic therapy after biopros-
thetic aortic valve replacement,
guidelines from major international
cardiology and cardiac surgery socie-
ties continue to recommend antithrom-
botic therapy for 90 days after
bioprosthetic aortic valve replacement.
Although there have been attempts
at performing a prospective randomized
controlled trial to definitively answer
this question and establish a standard
of care,2,3 these studies have been
grossly underpowered, containing no
more than 150 patients in each group.
Depending on the parameters used to
performapower analysis, a conservative
estimate for conducting a randomized
controlled trial with an effective power
(b> 80%) would consist of at least
1500 patients in each group. As the au-
thors describe, conducting such a study
would require enrollment from multiple
high-volume centers.
The controversy and need for level 1
evidence regarding this topic are illus-
trated by the variability in antithrom-
botic therapy regimens, which has
been documented in the literature (pri-
marily in the United Kingdom).4 An-
ecdotally, in the United States, we
know of institutions and surgeons
that routinely anticoagulate with intra-
venous heparin followed by warfarin
sodium and those that provide no anti-
coagulation whatsoever. These vary-
ing practices and unclear data should
provide incentive to funding agencies
to further study this question. On one
hand, we may be placing patients at
a high risk of major bleeding events
and on the other hand, we may notCardiovascular Surgery c November 20be adequately protecting patients
from the risk of embolism. In the
meantime, however, we believe it is
important that we use the best
available evidence, which is to avoid
routine anticoagulation except in
high-risk patients.1
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ENDOVASCULAR TREATMENT
FOR TYPE B AORTIC
DISSECTIONSTo the Editor:
We read with great interest the man-
uscript by Xu and associates,1 in
which they presented their early and
midterm results of endovascular repair
for the treatment of type B aortic dis-
sections.
Although the Stanford classification
is frequently used in the current era,
the DeBakey classification seems more10
